Path Grand Rounds: Monitoring of residual acute leukemia in the clinical laboratory.

This event has ended.

Speaker

Brent L. Wood, MD, PhD
Professor, Laboratory Medicine and Pathology
Division, Hematopathology
University of Washington


Date & Time

September 7, 2016 at 12:00pm - 1:00pm

Location

UWMC, NE110 Conference Room

Calendar

Path Grand Rounds

Export
Add to Calendar 09/07/2016 12:00 PM 09/07/2016 01:00 PM America/Los_Angeles Path Grand Rounds: Monitoring of residual acute leukemia in the clinical laboratory. Path Grand Rounds: Monitoring of residual acute leukemia in the clinical laboratory.

Brent L. Wood, MD, PhD
Professor, Laboratory Medicine and Pathology
Division, Hematopathology
University of Washington
Why Attend? Monitoring of residual acute leukemia in the clinical laboratory. The enumeration of residual leukemia after therapy is rapidly becoming the standard of care for monitoring response in patients with acute leukemia. This talk will present the current state-of-the-art for flow cytometric and next-generation sequencing approaches to residual disease assessment in acute leukemia and discuss their clinical significance. Reference PMID: 26668349   After viewing this lecture, attendees should be able to: 1.  List the major methods used for laboratory monitoring of residual acute leukemia. 2.  Recite the basic principle of immunophenotyping for hematopoietic neoplasms. 3.  Describe the advantages and limitations of flow cytometry and NGS for residual disease monitoring.
UWMC, NE110 Conference Room false MM/DD/YYYY

Description

Why Attend?

Monitoring of residual acute leukemia in the clinical laboratory.

The enumeration of residual leukemia after therapy is rapidly becoming the standard of care for monitoring response in patients with acute leukemia. This talk will present the current state-of-the-art for flow cytometric and next-generation sequencing approaches to residual disease assessment in acute leukemia and discuss their clinical significance.

Reference PMID: 26668349

 

After viewing this lecture, attendees should be able to:

1.  List the major methods used for laboratory monitoring of residual acute leukemia.

2.  Recite the basic principle of immunophenotyping for hematopoietic neoplasms.

3.  Describe the advantages and limitations of flow cytometry and NGS for residual disease monitoring.